Lynx1 Capital Management LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001910456

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 27 positions · Total reported value $865.53M · Top-10 concentration 98.8% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 51.7% · 6 new · 7 cut · 2 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +34.0% · vs SPY +19.1% · Prev Value $632.72M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Lynx1 Capital Management LP disclosed 27 equity positions with a combined reported value of $865.53M. The filing implies a focused portfolio: its ten largest positions account for 98.8% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were GHRS ($356.52M), CGEM ($163.23M), STOK ($132.14M). By sector, the heaviest allocations are Health Care 99.9%, Other 0.1%.

Versus the prior quarter, Lynx1 Capital Management LP opened 6 new positions, trimmed 7 and fully exited 2, a turnover rate of 51.7% of positions. The portfolio's overlap with the prior quarter was 72% of names.

The largest new positions opened in Q2 2026 were PLRX ($2.05M), FHTX ($300.55K), AVTX ($186.65K).

Of the 2 positions fully exited versus the prior quarter, the largest were DSGN ($1.27M), IBIO ($129.34K).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • PLRX PLIANT THERAPEUTICS INC · $2.05M
  • FHTX FOGHORN THERAPEUTICS INC · $300.55K
  • AVTX AVALO THERAPEUTICS INC · $186.65K
  • NUVB NUVATION BIO INC · $91.05K
  • EPRX EUPRAXIA PHARMACEUTICALS INC · $66.10K
  • IKT INHIBIKASE THERAPEUTICS INC · $40.60K

Fully Exited (vs previous quarter)

  • DSGN DESIGN THERAPEUTICS INC · prev qtr: $1.27M
  • IBIO IBIO INC · prev qtr: $129.34K

Insider Transactions (Form 4)

Latest Lynx1 Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-26 Buy Korro Bio, Inc. 25,124 $11.75 SEC filing
2026-10-23 Buy Korro Bio, Inc. 2,510 $12.11 SEC filing
2026-10-22 Buy Korro Bio, Inc. 40,000 $11.04 SEC filing
2026-10-22 Buy Korro Bio, Inc. 12,175 $9.68 SEC filing
2026-08-10 Buy Korro Bio, Inc. 1,462 $13.19 SEC filing
2026-08-06 Buy Korro Bio, Inc. 5,222 $11.40 SEC filing
2026-06-25 Buy Passage BIO, Inc. 50,055 $4.12 SEC filing

All insider transactions →

Fund Profile

Lynx1 Capital Management LP, based in Dorado, PR, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 27 positions worth $865.53M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: DORADO, PR, United States
  • SEC registration: 801-127585 (status: Approved), registered 2023-04-05
  • Regulatory AUM (Form ADV): $626.68M as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 1 hedge funds

Portfolio Structure

  • 27 positions · $865.53M reported value (Q2 2026)
  • Top 10 holdings = 98.8% of reported value
  • Largest position: GHRS (GH RESEARCH PLC) at 41.2%
  • Average position size: $32.06M

Sector Tilt

  • Health Care 99.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 6 added, 7 reduced, 2 exited
  • 8 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Lynx1 Capital Management LP appears to be maintaining a cautious approach with a focus on health care sector, suggesting a belief in the potential for growth within this sector. The slight increase in holdings from the previous quarter and the addition of new positions indicate a willingness to take on some additional risk. 2. Key Moves: - Added: GHRS (GH RESEARCH PLC) by 23.2% in shares, indicating a strong positive stance on the company. AGIO (AGIOS PHARMACEUTICALS INC COMP) also saw a significant increase of 30.5% in shares, signaling a favorable view on this stock. - Reduced: STOK (STOKE THERAPEUTICS INC) by 15.2% in shares, possibly reflecting concerns or a shift in the company's prospects. DTIL (PRECISION BIOSCIENCES INC) saw a minor reduction of 3.5%. - Hold: The majority of holdings were held steady, with no significant changes in share count. 3. Portfolio Structure: - The portfolio appears to be actively managed rather than passive, as evidenced by the changes in share counts and the addition of new positions. - The sector bias is clearly toward health care, which represents over 60% of the portfolio value. - The risk appetite seems moderate, as the fund is not heavily diversified but is not taking on extreme risk either. 4. Per-Holding One-Liner: - GHRS: GH RESEARCH PLC, a biopharmaceutical company focusing on the development of novel therapies for cancer. - CGEM: CULLINAN THERAPEUTICS INC, a biotechnology company developing novel cancer immunotherapies. - STOK: STOKE THERAPEUTICS INC, a biotechnology company focused on developing treatments for neurological disorders. - AGIO: AGIOS PHARMACEUTICALS INC COMP, a biopharmaceutical company dedicated to developing novel cancer therapies. - CCCC: C4 THERAPEUTICS INC, a biotechnology company focused on the development of therapies for cardiovascular diseases. - KRRO: KORRO BIO INC, a biotechnology company focusing on the development of treatments for rare genetic diseases. - TCRX: TScan Therapeutics Inc, a biotechnology company focusing on the development of therapies for cancer. - DTIL: PRECISION BIOSCIENCES INC, a biotechnology company specializing in gene editing technologies. - NEUP: NEUPHORIA THERAPEUTICS INC, a biotechnology company focusing on the development of treatments for rare genetic diseases. - PASG: Passage Bio Inc, a biotechnology company focused on the development of treatments for rare genetic diseases. 5. One-Sentence Style Summary: Lynx1 Capital Management LP maintained a cautious stance, increasing its focus on health care while selectively adding new positions and adjusting existing holdings in the latest quarter.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 99.9%
Other 0.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 13.26M $356.52M 41.19%
41.19%
Add
2 8.96M $163.23M 18.86%
18.86%
Hold
3 4.04M $132.14M 15.27%
15.27%
Reduce
4 3.41M $126.51M 14.62%
14.62%
Add
5 7.33M $34.22M 3.95%
3.95%
Add
6 1.54M $20.27M 2.34%
Form 4 · 4 →
2.34%
Hold
7 8.02M $7.86M 0.91%
0.91%
Hold
8 950.47K $7.47M 0.86%
0.86%
Reduce
9 875.33K $3.83M 0.44%
0.44%
Hold
10 673.76K $3.29M 0.38%
0.38%
Add
11 31.39K $2.23M 0.26%
0.26%
Reduce
12 1.80M $2.05M 0.24%
0.24%
New
13 178.61K $1.31M 0.15%
0.15%
Reduce
14 1.63M $1.06M 0.12%
0.12%
Hold
15 521.41K $969.83K 0.11%
0.11%
Add
16 559.47K $471.80K 0.06%
0.06%
Add
17 61.59K $300.55K 0.04%
0.04%
New
18 11.66K $299.84K 0.04%
0.04%
Reduce
19 18.19K $292.92K 0.03%
0.03%
Reduce
20 21.25K $246.23K 0.03%
0.03%
Hold
21 657.79K $236.74K 0.03%
0.03%
Hold
22 23.24K $235.38K 0.03%
0.03%
Reduce
23 10.10K $186.65K 0.02%
0.02%
New
24 30.80K $118.58K 0.01%
0.01%
Hold
25 16.03K $91.05K 0.01%
0.01%
New
26 10.00K $66.10K 0.01%
0.01%
New
27 20.00K $40.60K 0.01%
0.01%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 80% R 80% F1 80% (modelled on 2026-Q1; 8/10 hit)

Low-confidence forecast This fund replaces about 21% of its Top-10 each quarter and backtests at F1 79% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 79% · recall 79% · F1 79% · avg rank error 1.7 · Top-10 turnover 21%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 90% 90% 90% ALPN · CABA · MRUS · TCRX · CCCC · STOK · AUTL · GHRS · KNTE · SLN ALPN · MRUS · STOK · TCRX · CABA · GHRS · CCCC · SLN · AUTL · PASG
2024-Q2 70% 70% 70% ALPN · MRUS · STOK · TCRX · GHRS · CABA · CCCC · SLN · AUTL · PASG MRUS · STOK · GHRS · CCCC · TCRX · CGEM · ALLO · LBPH · PASG · CABA
2024-Q3 80% 80% 80% STOK · MRUS · GHRS · CCCC · TCRX · CGEM · ALLO · PASG · LBPH · CABA MRUS · STOK · CCCC · GHRS · TCRX · ALLO · CGEM · PASG · IBIO · CRBU
2024-Q4 80% 80% 80% MRUS · STOK · CCCC · GHRS · TCRX · ALLO · CGEM · PASG · IBIO · CRBU MRUS · STOK · GHRS · CCCC · ALLO · TCRX · CGEM · KROS · PASG · ALLK
2025-Q1 70% 70% 70% MRUS · STOK · GHRS · ALLO · CCCC · CGEM · TCRX · KROS · PASG · ALLK GHRS · MRUS · PTGX · STOK · CGEM · ALLO · CCCC · TCRX · DTIL · IBIO
2025-Q2 90% 90% 90% GHRS · MRUS · PTGX · STOK · CGEM · ALLO · CCCC · TCRX · DTIL · IBIO MRUS · GHRS · STOK · PTGX · CGEM · ALLO · TCRX · CCCC · DTIL · PASG
2025-Q3 90% 90% 90% GHRS · MRUS · STOK · PTGX · CGEM · ALLO · TCRX · CCCC · DTIL · PASG MRUS · STOK · GHRS · PTGX · CGEM · CCCC · TCRX · DTIL · ADCT · PASG
2025-Q4 60% 60% 60% MRUS · STOK · GHRS · PTGX · CGEM · CCCC · TCRX · DTIL · ADCT · PASG STOK · GHRS · CGEM · DNLI · CCCC · XNCR · IMTX · TCRX · PASG · KRRO
2026-Q1 80% 80% 80% STOK · GHRS · CGEM · DNLI · CCCC · XNCR · IMTX · TCRX · PASG · KRRO STOK · GHRS · CGEM · AGIO · DNLI · CCCC · KRRO · TCRX · XNCR · DTIL
2026-Q2 ★ 80% 80% 80% GHRS · STOK · CGEM · AGIO · DNLI · KRRO · CCCC · TCRX · XNCR · DTIL GHRS · CGEM · STOK · AGIO · CCCC · KRRO · TCRX · DTIL · NEUP · PASG

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Lynx1 Capital Management LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Lynx1 Capital Management LP reported 27 equity positions worth $865.53M in aggregate; its largest disclosed positions were GHRS ($356.52M), CGEM ($163.23M), STOK ($132.14M).

How large is Lynx1 Capital Management LP's portfolio?

Lynx1 Capital Management LP reported $865.53M of long equity holdings across 27 positions as of 2026-Q2. Top-10 holdings account for 98.8% of reported value.

What is Lynx1 Capital Management LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/lynx1-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →